RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Coherus BioSciences Stock

Coherus BioSciences ROCE 2024

Coherus BioSciences ROCE

1.03

Ticker

CHRS

ISIN

US19249H1032

WKN

A12ETZ

In 2024, Coherus BioSciences's return on capital employed (ROCE) was 1.03, a -45.13% increase from the 1.87 ROCE in the previous year.

Coherus BioSciences Aktienanalyse

What does Coherus BioSciences do?

Coherus BioSciences Inc is a pharmaceutical company specializing in the development and marketing of biosimilars. The company was founded in California in 2010 and has since focused on the development of biopharmaceuticals. Coherus BioSciences Inc's history began with the acquisition of the biomanufacturing facility from PDL BioPharma, a company specialized in the development and marketing of therapeutics and biologics. Coherus BioSciences Inc used the facility to build a portfolio of biosimilars. Coherus BioSciences Inc's business model is based on the sale of biosimilars, which offer a cost-effective alternative to expensive biologics. Biosimilars are biopharmaceuticals that are manufactured similarly to already approved biologics, but can be offered at a lower price. Coherus BioSciences Inc specializes in the development and marketing of biosimilars in the fields of oncology, immunology, and neurology. The products that the company currently brings to market or is developing include biosimilar versions of Enbrel, Neulasta, and Humira. Enbrel is a biologic used to treat rheumatoid arthritis, psoriasis, and other inflammatory conditions. Neulasta is a medication used to support white blood cells after chemotherapy, while Humira is a medication used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. Coherus BioSciences Inc has also launched a collaboration with Novartis to develop a biosimilar version of Lucentis. Lucentis is a biologic used to treat age-related macular degeneration. Overall, Coherus BioSciences Inc has built a portfolio of ten biosimilars and is working to bring more products to market. The company has also conducted several preclinical and clinical studies to demonstrate the efficacy and safety of its biosimilars. Coherus BioSciences Inc is headquartered in Redwood City, California. The company currently employs over 140 employees and has offices in the USA, Europe, and Asia. Overall, Coherus BioSciences Inc has played a groundbreaking role in the development of cost-effective biosimilars. The company specializes in the marketing of biosimilars and offers a range of products in the fields of oncology, immunology, and neurology. Coherus BioSciences Inc has also launched a collaboration with another company to develop a biosimilar version of Lucentis. The company has built a portfolio of ten biosimilars and is constantly expanding its offerings. Coherus BioSciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Coherus BioSciences's Return on Capital Employed (ROCE)

Coherus BioSciences's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Coherus BioSciences's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Coherus BioSciences's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Coherus BioSciences’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Coherus BioSciences stock

What is the ROCE (Return on Capital Employed) of Coherus BioSciences this year?

The ROCE of Coherus BioSciences is 1.03 undefined this year.

How has the ROCE (Return on Capital Employed) of Coherus BioSciences developed compared to the previous year?

The ROCE of Coherus BioSciences has increased by -45.13% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Coherus BioSciences?

A high Return on Capital Employed (ROCE) indicates that Coherus BioSciences has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Coherus BioSciences?

A low ROCE (Return on Capital Employed) can indicate that Coherus BioSciences has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Coherus BioSciences impact the company?

An increase in the ROCE of Coherus BioSciences can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Coherus BioSciences affect the company?

A decrease in ROCE of Coherus BioSciences can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Coherus BioSciences?

Some factors that can affect Coherus BioSciences's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Coherus BioSciences so important for investors?

The ROCE of Coherus BioSciences is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Coherus BioSciences take to improve the ROCE?

To improve the ROCE, Coherus BioSciences can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Coherus BioSciences pay?

Over the past 12 months, Coherus BioSciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Coherus BioSciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Coherus BioSciences?

The current dividend yield of Coherus BioSciences is .

When does Coherus BioSciences pay dividends?

Coherus BioSciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Coherus BioSciences?

Coherus BioSciences paid dividends every year for the past 0 years.

What is the dividend of Coherus BioSciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Coherus BioSciences located?

Coherus BioSciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Coherus BioSciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Coherus BioSciences from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did Coherus BioSciences pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of Coherus BioSciences in the year 2023?

In the year 2023, Coherus BioSciences distributed 0 USD as dividends.

In which currency does Coherus BioSciences pay out the dividend?

The dividends of Coherus BioSciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Coherus BioSciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Coherus BioSciences

Our stock analysis for Coherus BioSciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Coherus BioSciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.